Compare MMA & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMA | XLO |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 39.4M |
| IPO Year | 2023 | 2021 |
| Metric | MMA | XLO |
|---|---|---|
| Price | $0.45 | $8.45 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | ★ 456.8K | 264.1K |
| Earning Date | 05-20-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,766,000.00 |
| Revenue This Year | N/A | $88.66 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 589.88 |
| 52 Week Low | $0.35 | $0.46 |
| 52 Week High | $2.88 | $9.25 |
| Indicator | MMA | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 42.57 | 88.35 |
| Support Level | $0.35 | $0.63 |
| Resistance Level | $0.71 | N/A |
| Average True Range (ATR) | 0.06 | 0.49 |
| MACD | 0.02 | 0.45 |
| Stochastic Oscillator | 59.39 | 90.50 |
Mixed Martial Arts Group Ltd is a technology company operating in the martial arts and combat sports industry. The company operate four core business units: i) TrainAlta: A platform that transforms MMA fans into active participants through structured training programs like the Warrior Training Program, ii) BJJLink: A gym management platform designed for BJJ academies, offering tools for payment processing, marketing, student engagement, and content monetization, iii) Hype: A marketing platform helping gym owners, coaches, and athletes grow revenue from their audiences, iv) MixedMartialArts.com: The go-to resource for MMA news, fighter data, fight schedules, and the legendary Underground forum. Its majority of revenue is in the form of Program revenue, which consists of the license fees.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.